Seizure amelioration effect of omega-3 EPA and DHA fatty acid supplementation on patients with drug resistant epilepsy: a scoping review using the GOED clinical study database
Objectives: 70% of patients with epilepsy are successfully treated with one or a combination of anti-seizure medications (ASMs). The latter 30%, do not respond to ASMs and continue to have uncontrollable seizures. They are known to have drug-resistant epilepsy (DRE). There is an unmet need for non...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024
|
| Subjects: | |
| Online Access: | https://repository.londonmet.ac.uk/9488/1/PIIS2475299124011557.pdf |
| _version_ | 1824446468907335680 |
|---|---|
| author | Abuknesha, Nada R. Searle, Andrew J. |
| author_facet | Abuknesha, Nada R. Searle, Andrew J. |
| author_sort | Abuknesha, Nada R. |
| collection | LMU |
| description | Objectives:
70% of patients with epilepsy are successfully treated with one or a combination of anti-seizure medications (ASMs). The latter 30%, do not respond to ASMs and continue to have uncontrollable seizures. They are known to have drug-resistant epilepsy (DRE). There is an unmet need for non-pharmacological treatment options to be considered. The objective of this scoping review is to assess the seizure amelioration effect of omega-3 (n-3) polyunsaturated fatty acids (PUFAs): eicosapentaenoic (EPA) and docosahexaenoic (DHA) acids on patients with DRE from randomized human clinical trials (RCTs).
Methods:
The Global Organization for EPA & DHA Omega-3s (GOED) Clinical Study Database was used as the primary search tool to generate a list of RCTs using the following terms: seizures, seizure severity, drug resistant epilepsy, refractory epilepsy, and intractable epilepsy. Subsequently, PubMed and Google Scholar English databases were searched for publications using the additional keywords: eicosapentaenoic acid and docosahexaenoic acid.
Results:
Eleven RCTs published before October 2023 were included in this review. EPA and DHA formulations administered to patients ranged between 0.3-2.9g/day, with 90.9% of RCTs investigating the fatty acids at a comparable ratio. A supplementation period of 3 months or less was employed by 72.7% of RCTs. 54.5% of RCTs reported a positive outcome of at least 50% or more significant reduction in seizure frequency compared to placebo or baseline. 27.2% of RCTs reported significant seizure freedom in patients during or at the end of the supplementation period, compared to placebo. Positive outcomes regarding seizure severity remain inconsistent with only 18.1% of RCTs reporting a significant reduction compared to placebo or baseline.
Conclusions:
N-3 EPA and DHA have the potential to be a simple add-on treatment intervention for the management of uncontrollable seizures in DRE. Additional RCTs are required to determine the optimal dosage for patients, the effect of long-term treatment duration and separately enriched preparations of EPA/DHA on seizure frequency and severity. |
| first_indexed | 2025-02-19T01:15:39Z |
| format | Article |
| id | oai:repository.londonmet.ac.uk:9488 |
| institution | London Metropolitan University |
| language | English |
| last_indexed | 2025-02-19T01:15:39Z |
| publishDate | 2024 |
| publisher | Elsevier |
| record_format | eprints |
| spelling | oai:repository.londonmet.ac.uk:94882024-07-09T11:11:10Z https://repository.londonmet.ac.uk/9488/ Seizure amelioration effect of omega-3 EPA and DHA fatty acid supplementation on patients with drug resistant epilepsy: a scoping review using the GOED clinical study database Abuknesha, Nada R. Searle, Andrew J. 610 Medicine & health Objectives: 70% of patients with epilepsy are successfully treated with one or a combination of anti-seizure medications (ASMs). The latter 30%, do not respond to ASMs and continue to have uncontrollable seizures. They are known to have drug-resistant epilepsy (DRE). There is an unmet need for non-pharmacological treatment options to be considered. The objective of this scoping review is to assess the seizure amelioration effect of omega-3 (n-3) polyunsaturated fatty acids (PUFAs): eicosapentaenoic (EPA) and docosahexaenoic (DHA) acids on patients with DRE from randomized human clinical trials (RCTs). Methods: The Global Organization for EPA & DHA Omega-3s (GOED) Clinical Study Database was used as the primary search tool to generate a list of RCTs using the following terms: seizures, seizure severity, drug resistant epilepsy, refractory epilepsy, and intractable epilepsy. Subsequently, PubMed and Google Scholar English databases were searched for publications using the additional keywords: eicosapentaenoic acid and docosahexaenoic acid. Results: Eleven RCTs published before October 2023 were included in this review. EPA and DHA formulations administered to patients ranged between 0.3-2.9g/day, with 90.9% of RCTs investigating the fatty acids at a comparable ratio. A supplementation period of 3 months or less was employed by 72.7% of RCTs. 54.5% of RCTs reported a positive outcome of at least 50% or more significant reduction in seizure frequency compared to placebo or baseline. 27.2% of RCTs reported significant seizure freedom in patients during or at the end of the supplementation period, compared to placebo. Positive outcomes regarding seizure severity remain inconsistent with only 18.1% of RCTs reporting a significant reduction compared to placebo or baseline. Conclusions: N-3 EPA and DHA have the potential to be a simple add-on treatment intervention for the management of uncontrollable seizures in DRE. Additional RCTs are required to determine the optimal dosage for patients, the effect of long-term treatment duration and separately enriched preparations of EPA/DHA on seizure frequency and severity. Elsevier 2024-07-31 Article PeerReviewed text en cc_by_nc_nd_4 https://repository.londonmet.ac.uk/9488/1/PIIS2475299124011557.pdf Abuknesha, Nada R. and Searle, Andrew J. (2024) Seizure amelioration effect of omega-3 EPA and DHA fatty acid supplementation on patients with drug resistant epilepsy: a scoping review using the GOED clinical study database. Current Developments in Nutrition, 8 (2) (103221). pp. 455-456. ISSN 24752991 https://doi.org/10.1016/j.cdnut.2024.103221 10.1016/j.cdnut.2024.103221 10.1016/j.cdnut.2024.103221 |
| spellingShingle | 610 Medicine & health Abuknesha, Nada R. Searle, Andrew J. Seizure amelioration effect of omega-3 EPA and DHA fatty acid supplementation on patients with drug resistant epilepsy: a scoping review using the GOED clinical study database |
| title | Seizure amelioration effect of omega-3 EPA and DHA fatty acid supplementation on patients with drug resistant epilepsy: a scoping review using the GOED clinical study database |
| title_full | Seizure amelioration effect of omega-3 EPA and DHA fatty acid supplementation on patients with drug resistant epilepsy: a scoping review using the GOED clinical study database |
| title_fullStr | Seizure amelioration effect of omega-3 EPA and DHA fatty acid supplementation on patients with drug resistant epilepsy: a scoping review using the GOED clinical study database |
| title_full_unstemmed | Seizure amelioration effect of omega-3 EPA and DHA fatty acid supplementation on patients with drug resistant epilepsy: a scoping review using the GOED clinical study database |
| title_short | Seizure amelioration effect of omega-3 EPA and DHA fatty acid supplementation on patients with drug resistant epilepsy: a scoping review using the GOED clinical study database |
| title_sort | seizure amelioration effect of omega 3 epa and dha fatty acid supplementation on patients with drug resistant epilepsy a scoping review using the goed clinical study database |
| topic | 610 Medicine & health |
| url | https://repository.londonmet.ac.uk/9488/1/PIIS2475299124011557.pdf |
| work_keys_str_mv | AT abukneshanadar seizureameliorationeffectofomega3epaanddhafattyacidsupplementationonpatientswithdrugresistantepilepsyascopingreviewusingthegoedclinicalstudydatabase AT searleandrewj seizureameliorationeffectofomega3epaanddhafattyacidsupplementationonpatientswithdrugresistantepilepsyascopingreviewusingthegoedclinicalstudydatabase |